Tag: Vaxxas

Australian biotechnology company Vaxxas has been granted a Therapeutic Goods Administration licence to manufacture therapeutic goods, clearing the way for GMP-compliant manufacturing at its Brisbane biomedical facility and supporting the progression of clinical trials for its proprietary high-density microarray patch technology.

Vaxxas Pty Ltd has secured around $90 million in new funding to accelerate the commercialisation and manufacturing of its needle-free vaccine delivery technology.

Australian biotechnology company Vaxxas has completed enrollment for its largest clinical trial to date, testing the safety and immune response of its high-density microarray patch (HD-MAP) for vaccine delivery. 

Vaxxas, a clinical-stage biotechnology company specializing in high-density microarray patch (HD-MAP) vaccine delivery, has been awarded a $2 million (AUD 3.2 million) grant as a Concept Stage winner in the United States Biomedical Advanced Research and Development Authority’s (BARDA) $50 million Patch Forward Prize. 

Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV). 

Biotechnology company Vaxxas has completed work on its new needle-free vaccine technology manufacturing facility in Northshore Hamilton. 

Australia biotechnology company Vaxxas said it achieved positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate. 

Two projects involving medical and scientific researchers from the University of Sydney have secured government funding through the Cooperative Research Centres Projects’ (CRC-P) latest round. 

Vaxxas has commenced the Phase I clinical trial of the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate via its proprietary high-density microarray patch (HD-MAP) technology.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has announced it has completed a financing round which raised US$23 million (A$34 million) in new funds.